http://healthcarecollaboration.com/an-interview-with-stuart-h-altman/?utm_source=rss&utm_medium=rss&utm_campaign=an-interview-with-stuart-h-altman Fri, 30 Mar 2012 09:40:45 +0000 hourly 1 http://wordpress.org/?v=3.3.2 http://healthcarecollaboration.com/an-interview-with-stuart-h-altman/#comment-141 A Massachusetts Surgeon Weighs in on the Meaning of Scott Brown’s Senate Victory: Post 81 | Healthcare Collaboration Sun, 24 Jan 2010 17:39:38 +0000 http://healthcarecollaboration.com/?p=94#comment-141 [...] An Interview with Stuart Altman, this distinguished healthcare economist mentioned Altman’s Law, that  advocacy groups seek to [...] [...] An Interview with Stuart Altman, this distinguished healthcare economist mentioned Altman’s Law, that  advocacy groups seek to [...]

]]> http://healthcarecollaboration.com/an-interview-with-stuart-h-altman/#comment-140 lieben Tue, 03 Mar 2009 09:33:18 +0000 http://healthcarecollaboration.com/?p=94#comment-140 Interessante Informationen. Interessante Informationen.

]]> http://healthcarecollaboration.com/an-interview-with-stuart-h-altman/#comment-139 Stuart Altman Thu, 08 Jan 2009 19:36:14 +0000 http://healthcarecollaboration.com/?p=94#comment-139 Here is Dr. Altman's reply: You questioned whether we should include pharmaceutical companies in the discussion of healthcare reform. In my view absolutely. This does not mean that they will be able to dominate or necessarily get their way but their issues need to be discussed. After all many of us depend on the products they produce to continue functioning. Here is Dr. Altman’s reply:
You questioned whether we should include pharmaceutical companies in the discussion of healthcare reform. In my view absolutely. This does not mean that they will be able to dominate or necessarily get their way but their issues need to be discussed. After all many of us depend on the products they produce to continue functioning.

]]> http://healthcarecollaboration.com/an-interview-with-stuart-h-altman/#comment-137 G.L. Keel Wed, 07 Jan 2009 14:11:39 +0000 http://healthcarecollaboration.com/?p=94#comment-137 I would like to hear from Dr. Altman about whether he considers pharmaceutical interests "stakeholders who need to be a part of any compromise." How do we limit capture by such interests, especially when past policy choices favor them and increase costs (prescription drug coverage as a new entitlement)? Also, how might we create incentives for individuals to alter their lifestyle choices that contribute to widespread diseases and expensive treatments (diabetes, heart d, stroke, cancer)? Sugar and fat taxes seem to challenge Americans' cherished belief in personal liberty. I would like to hear from Dr. Altman about whether he considers pharmaceutical interests “stakeholders who need to be a part of any compromise.” How do we limit capture by such interests, especially when past policy choices favor them and increase costs (prescription drug coverage as a new entitlement)?
Also, how might we create incentives for individuals to alter their lifestyle choices that contribute to widespread diseases and expensive treatments (diabetes, heart d, stroke, cancer)? Sugar and fat taxes seem to challenge Americans’ cherished belief in personal liberty.

]]> http://healthcarecollaboration.com/an-interview-with-stuart-h-altman/#comment-138 elaine arkin Tue, 06 Jan 2009 21:39:23 +0000 http://healthcarecollaboration.com/?p=94#comment-138 From a Brandeis email. sounds like David Helms might know him From a Brandeis email. sounds like David Helms might know him

]]>